Mild Dry Eye Market Growth Projections 2023-2032: DelveInsight Analysis | Palatin Technologies, Novaliq, mc2 therapeutics

The Key Mild Dry Eye Companies in the market include - Palatin Technologies, Novaliq, mc2 therapeutics, and others.

The Mild Dry Eye market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Mild Dry Eye pipeline products will significantly revolutionize the Mild Dry Eye market dynamics.

DelveInsight's "Mild Dry Eye Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Mild Dry Eye, historical and forecasted epidemiology as well as the Mild Dry Eye market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Mild Dry Eye market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Mild Dry Eye market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Mild Dry Eye Market Forecast [https://www.delveinsight.com/sample-request/mild-dry-eye-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Mild Dry Eye Market Report:

*
The Mild Dry Eye market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

*
In May 2025, Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) has announced that it will hold a webcast and conference call on Tuesday, May 6, 2025, at 8:00 a.m. ET to present the topline results from its Phase 3 clinical trials of reproxalap for dry eye disease. U.S. participants can dial (833) 470-1428, while international callers can use (404) 975-4839, using access code 127477. A live audio webcast will be available in the "Investors & Media" section of Aldeyra's website at ir.aldeyra.com. The recording will remain accessible on the site for 90 days following the event.

*
In April 2025, The U.S. Food and Drug Administration (FDA) declined to approve Aldeyra Therapeutics' Dry Eye treatment, reproxalap, citing insufficient efficacy data. This marks the second rejection, following a similar outcome in 2023. The FDA recommends at least one additional trial to demonstrate the drug's effectiveness.

*
In February 2025, Cambium Bio revealed that the FDA has approved the protocol for its Phase III clinical trials of Elate Ocular, aimed at treating moderate to severe Dry Eye.

*
In January 2025, Stuart Therapeutics, Inc. (Stuart), a clinical-stage drug platform company focused on developing innovative treatments for ophthalmic conditions, has announced the completion of the final patient visit in its Phase III clinical trial of ST-100 (vezocolmitide), its lead therapeutic candidate for Dry Eye.

*
In December 2024, The FDA issued a nationwide recall of a specific single-use eye drop product. Alcon Laboratories voluntarily recalled one lot (Lot 10101) of Systane Lubricant Eye Drops Ultra PF, Single Vials On-the-Go, 25 count, after a customer reported possible fungal contamination in a vial. This recall is limited to the identified lot only.

*
In August 2024, Aldeyra Therapeutics, Inc. (Nasdaq: ALDX), a biotechnology company focused on discovering and developing innovative therapies for immune-mediated and metabolic diseases, today announced the achievement of the primary endpoint in a Phase 3 randomized, double-masked, vehicle-controlled clinical trial of 0.25% reproxalap ophthalmic solution. This investigational drug candidate aims to treat Dry Eye. Reproxalap showed statistical superiority to the vehicle for the prespecified primary endpoint of ocular discomfort (P=0.004), a symptom of Mild Dry Eye accepted by the U.S. Food and Drug Administration (FDA).

*
In January 2024, Alcon, headquartered in Switzerland, announced the success of its Dry Eye medication AR-15512 in meeting primary endpoints in two Phase III trials, namely COMET-2 and COMET-3. With encouraging results from these trials, the company intends to submit a new drug application (NDA) for AR-15512 to the US Food and Drug Administration (FDA) by mid-2024, as outlined in a press release dated January 9th.

*
In January 2024, Stuart Therapeutics, a biopharmaceutical firm based in the United States, has initiated a Phase III clinical study for their drug candidate vezocolmitide (ST-100) targeting patients with Mild Dry Eye. This randomized, placebo-controlled trial seeks to assess the effectiveness and safety of a single dose of the ophthalmic solution compared to a placebo. The trial is set to enroll 320 participants

*
The anticipated launch of new therapies, including RGN-259, Tavilermide (MIM-D3), and AR-15512, is expected to drive changes in the total market size of DED in the coming years.

*
According to DelveInsight's assessment, the estimated total number of diagnosed prevalent cases of DED in the 7MM was approximately 54.7 million in 2023.

*
In 2023, the United Kingdom had the highest number of diagnosed prevalent cases of DED among European countries, with around 6.1 million cases, followed by Germany with approximately 5 million. Spain, meanwhile, had the lowest prevalence, with 2.1 million cases

*
Key Mild Dry Eye Companies: Palatin Technologies, Novaliq, mc2 therapeutics, and others

*
Key Mild Dry Eye Therapies: PL9643, NOV03, CyclASol, MC2-03, and others

*
The Mild Dry Eye epidemiology based on gender analyzed that females are more affected by Mild Dry Eye than males

Mild Dry Eye Overview

Mild dry eye is a common condition where the eyes do not produce enough tears or the tears evaporate too quickly, leading to insufficient lubrication. Symptoms may include slight eye discomfort, redness, a gritty or burning sensation, and occasional blurred vision. It is typically triggered by environmental factors, screen time, aging, or contact lens use. Though mild, if left unmanaged, it can worsen over time. Treatment often involves using over-the-counter artificial tears, taking screen breaks, staying hydrated, and managing environmental triggers.

Get a Free sample for the Mild Dry Eye Market Report -

https://www.delveinsight.com/report-store/mild-dry-eye-market [https://www.delveinsight.com/report-store/mild-dry-eye-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Mild Dry Eye Market

The dynamics of the Mild Dry Eye market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.

"Of the emerging therapies, MC2-03 (mc2 therapeutics), PL9643 (Palatin Technologies),and many other compelling treatments are expected to change the market scenario of Mild Dry Eye in the upcoming years."

Mild Dry Eye Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Mild Dry Eye Epidemiology Segmentation:

The Mild Dry Eye market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

*
Total Prevalence of Mild Dry Eye

*
Prevalent Cases of Mild Dry Eye by severity

*
Gender-specific Prevalence of Mild Dry Eye

*
Diagnosed Cases of Episodic and Chronic Mild Dry Eye

Download the report to understand which factors are driving Mild Dry Eye epidemiology trends @ Mild Dry Eye Epidemiological Insights [https://www.delveinsight.com/sample-request/mild-dry-eye-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Mild Dry Eye Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Mild Dry Eye market or expected to get launched during the study period. The analysis covers Mild Dry Eye market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Mild Dry Eye Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Mild Dry Eye Therapies and Key Companies

*
PL9643: Palatin Technologies

*
NOV03: Novaliq

*
CyclASol: Novaliq

*
MC2-03: mc2 therapeutics

To know more about Mild Dry Eye treatment, visit @ Mild Dry Eye Medications [https://www.delveinsight.com/sample-request/mild-dry-eye-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Scope of the Mild Dry Eye Market Report

*
Study Period: 2019-2032

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Mild Dry Eye Companies: Palatin Technologies, Novaliq, mc2 therapeutics, and others

*
Key Mild Dry Eye Therapies: PL9643, NOV03, CyclASol, MC2-03, and others

*
Mild Dry Eye Therapeutic Assessment: Mild Dry Eye current marketed and Mild Dry Eye emerging therapies

*
Mild Dry Eye Market Dynamics: Mild Dry Eye market drivers and Mild Dry Eye market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Mild Dry Eye Unmet Needs, KOL's views, Analyst's views, Mild Dry Eye Market Access and Reimbursement

Discover more about therapies set to grab major Mild Dry Eye market share @ Mild Dry Eye Treatment Landscape [https://www.delveinsight.com/sample-request/mild-dry-eye-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Mild Dry Eye Market Report Introduction

2. Executive Summary for Mild Dry Eye

3. SWOT analysis of Mild Dry Eye

4. Mild Dry Eye Patient Share (%) Overview at a Glance

5. Mild Dry Eye Market Overview at a Glance

6. Mild Dry Eye Disease Background and Overview

7. Mild Dry Eye Epidemiology and Patient Population

8. Country-Specific Patient Population of Mild Dry Eye

9. Mild Dry Eye Current Treatment and Medical Practices

10. Mild Dry Eye Unmet Needs

11. Mild Dry Eye Emerging Therapies

12. Mild Dry Eye Market Outlook

13. Country-Wise Mild Dry Eye Market Analysis (2019-2032)

14. Mild Dry Eye Market Access and Reimbursement of Therapies

15. Mild Dry Eye Market Drivers

16. Mild Dry Eye Market Barriers

17. Mild Dry Eye Appendix

18. Mild Dry Eye Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=mild-dry-eye-market-growth-projections-20232032-delveinsight-analysis-palatin-technologies-novaliq-mc2-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.